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Some studies suggest that small populations of CD4+ T cells with activation-independent, 
constitutive, NKG2D expression are found in normal peripheral blood and have immune 
suppressive properties.  The present study was designed to investigate NKG2D expres-
sion on CD4+ T lymphocytes and its relationship to immune evasion in colorectal can-
cer patients.  We examined NKG2D expression on both circulating and tumor infiltrat-
ing CD4+ and CD8+ T cells or NK cells and evaluated it by multicolor flow cytometry. 
Furthermore, intracellular cytokine staining was carried out to determine the cytokine 
profile of NKG2D+CD4+ T cells in colorectal cancer patients.  As a result, NKG2D ex-
pression on circulating and tumor-infiltrating CD8+ T cells and NK cells was downregu-
lated in colorectal cancer patients.  On the other hand, circulating and tumor-infiltrating 
NKG2D+CD4+ T cells increased in colorectal cancer patients.  NKG2D+CD4+ T cells 
produced more immune suppressive cytokines, such as interleukin-10 and transforming 
growth factor- 1, than did NKG2D-CD4+ T cells.  Increased NKG2D+CD4+ T cells as 
well as decreased NKG2D expression on CD8+ T cells and NK cells may be one of the key 
mechanisms responsible for immune evasion by tumors in colorectal cancer.
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T cells play an essential role in the immunosurveil-
lance and destruction of tumor cells.  Accumulat-
ing evidence indicates that specific T-cell immune 
responses can be raised against many tumors (Boon 
et al., 1994; Sahin et al., 1997).  Nonetheless, at-
tempts to translate this knowledge into clinically 
effective immunotherapies have met with only lim-
ited success (Dunn et al., 2004; Rosenberg et al., 
2004), because tumors develop mechanisms that 
allow them to escape host immune responses (Dunn 
et al., 2002; Whiteside, 2003).  One of the major 
mechanisms is the activity of T cells with negative 
immune regulatory function at tumor sites, which 
can markedly suppress immune responses and in-
duce immune tolerance (Woo et al., 2001; Liyanage 
et al., 2002; Curiel et al., 2004; Wang et al., 2004, 
2005).  Negative immune regulatory activity at tu-
mor sites has typically been attributed to regulatory 
T (Treg) cells.  A high density of tumor-infiltrating 
Foxp3+ Tregs has been associated with poor out-
comes in various solid tumors, including ovarian 
(Curiel et al., 2004; Sato et al., 2005), pancreatic 
(Hiraoka et al., 2006), and hepatocellular carci-
nomas (Gao et al., 2007; Kobayashi et al., 2007). 
Therefore, it is essential to understand the detailed 
mechanisms of immune cells with regulatory func-
tion in cancer patients to develop more effective 
immunotherapy.
 Recent findings suggest that other T cell 
subsets can function as suppressors of antitumor 
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immune responses (Shevach, 2002; Wang, 2006). 
One such T cell might be the NKG2D+CD4+ T 
cell.  NKG2D is a type II C-lectin-like protein 
encoded by a gene located next to the NKG2A, 
NKG2C and NKG2E genes within the natural 
killer (NK) gene complex on human chromosome 
12p12-p13 and mouse chromosome 6 (Glienke et 
al., 1998).  NKG2D is an activating cell surface 
receptor expressed by NK cells, gamma-delta T 
cells, some cytolytic CD8+ alpha-beta T cells and 
NKT cells (Bauer et al., 1999; Vivier et al., 2002; 
Raulet, 2003; Watzl, 2003).  In cancer patients, tu-
mor infiltrating and systemic NK cells and CD8+ 
T cells often express little NKG2D and are func-
tionally compromised (Groh et al., 2002).  On the 
other hand, small populations of CD4+ T cells 
with activation-independent, constitutive, NKG2D 
expression occur in normal peripheral blood (Bauer 
et al., 1999; Groh et al., 2006; Allez et al., 2007; 
Sundstrom et al., 2007).  Groh et al. (2006) recently 
demonstrated that increased populations of CD4+ 
T cells among tumor infiltrating lymphocytes (TILs) 
and in peripheral blood were positive for NKG2D 
in cancer patients with breast, lung, colon and 
ovarian carcinomas and melanomas.  They also 
showed that NKG2D+CD4+ T cells observed in 
cancer patients appeared biased toward an IL-10- 
and TGF-dominated cytokine profile, indicating 
that NKG2D+CD4+ T cells had immune suppres-
sive properties.  However, little is known about 
NKG2D+CD4+ T cells in cancer patients thus far.  
 Colorectal cancer is the fourth most com-
monly diagnosed malignancy, with an estimated 
1,023,000 new cases and 529,000 deaths each year 
(Parkin et al., 2005).  Considering the important 
function of immune cells with regulatory function, 
such as Tregs, in tumor progression and prognosis, 
it is extremely important to determine the presence 
of NKG2D+CD4+ T cells with immune suppres-
sive function in colorectal cancer patients.  Further-
more, NKG2D expression on CD8+ T cells and NK 
cells has not yet been determined in colorectal can-
cer.  In the present study, we determined NKG2D 
expression on CD4+ and CD8+ T cells and NK 
cells obtained from colorectal cancer patients.  We 
also analyzed the function of NKG2D+CD4+ T 
cells to investigate one of the mechanisms respon-
sible for immune evasion in patients with colorectal 
cancer.
 
 
Materials and Methods
 
Patients and normal donors 
 
Forty-two patients (22 males and 20 females), treat-
ed at Tottori University Hospital and pathologically 
diagnosed with colorectal cancer, were enrolled 
in this study.  None of the patients received radio-
therapy, chemotherapy or any other medical inter-
vention before donating blood.  Informed consent 
for blood donation was obtained from all individu-
als.  Patient characteristics are shown in Table 1. 
Healthy controls (n = 24; 18 males and 6 females) 
were age-matched (62.5 ± 8.9 years for the controls 
versus 65.3 ± 9.1 years for the patients), and each 
experiment was performed in parallel.  The clini-
copathological findings were determined according 
to the Japanese Classification of Colorectal Carci-
noma (Japanese Society for Cancer of the Colon 
and Rectum, 2009).
Preparation of peripheral blood mononu-
clear cells (PBMCs) 
 
An amount (40 mL) of peripheral blood was drawn 
from each of the controls and patients before sur-
gery or chemotherapy and PBMCs were separated 
by centrifugation over a Ficoll-Paque (Pharmacia, 
Uppsala, Sweden) gradient. 
Isolation of TILs
 
Freshly excised tumor tissues were minced and 
incubated in 1.5 mg/mL of collagenase D (Wako 
Pure Chemical Industries, Osaka, Japan).  Cell 
suspensions were then filtered through a mesh filter 
(BD Falcon, Franklin Lakes, NJ).
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Flow cytometry analysis
 
Flow cytometry analysis was performed on a FAC-
SCalibur (Becton Dickinson, Franklin Lakes, NJ), 
using the following antibodies: anti-CD3-PE-Cy5 
(Biolegend, San Diego, CA), anti-CD4-FITC, anti-
CD4-PE-Cy5, anti-CD8-FITC, anti-CD56-FITC 
and anti-NKG2D-PE (BD Pharmingen, Franklin 
Lakes, NJ).  For intracellular cytokine staining, 
PBMCs were cultured in the presence of either 
Leukocyte Activation Cocktail (BD Pharmingen) 
or lipopolysaccharide (Calbiochem, Darmstadt, 
Germany).  Anti-cytokine antibodies were anti-
IFN- -FITC (BD Pharmingen), anti-IL-10-Alexa 
fluor 488 (eBioscience, San Diego, CA) and anti-
LAP-TGF- 1-PerCP (R&D systems, Minneapolis, 
MN).  For the staining of IFN-  and IL-10, cells 
were fixed and permeabilized with BD Cytofix/
Cytoperm solution.
Media
 
Culture medium consisted of RPMI 1640 (Cambrex 
Bio Science Walkersville, Walkersville, MD), 1% 
penicillin/streptomycin (Invitrogen, Carlsbad, CA) 
and 10% heat-inactivated human serum AB (Gem-
ini Bio-Products, Woodlands, CA).  
Statistical analysis
 
To determine statistical differences between the 2 
groups, either paired t-tests or Mann-Whitney U-
tests were used.  The accepted level of significance 
was P < 0.05.  GraphPad Prism software (GraphPad 
Software, La Jolla, CA) was used for all statistical 
analyses.
 
Results
 
NKG2D expression on CD8+ T lymphocytes 
and NK cells in patients with colorectal can-
cer
 
NKG2D expression on circulating CD8+ T lym-
phocytes and NK cells is downregulated in various 
Fig. 1.  NKG2D expression on circulating CD8+ T cells 
or NK cells.
 a: Representative result of NKG2D expression on cir-
culating CD8+ T cells in either normal controls or 
colorectal cancer patients by FACS. 
b: NKG2D expression on circulating CD8+ T cells in 
colorectal cancer patients was significantly lower 
than in normal controls (P = 0.01). 
c: Representative result of NKG2D expression on 
circulating NK cells in either normal controls or 
colorectal cancer patients by FACS. 
d: NKG2D expression on circulating NK cells in col-
orectal cancer patients was significantly lower than 
in normal controls (P = 0.037).
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Fig. 3.  NKG2D expression on CD4+ T cells.
 a: Representative result of NKG2D expression on circulating CD4+ T cells in 
either normal controls or colorectal cancer patients by FACS. 
b: The frequency of NKG2D+CD4+ T cells in colorectal cancer patients was 
significantly higher than in normal controls (P = 0.048). 
c: The frequency of NKG2D+CD4+ T cells in tissue of colorectal cancer was 
significantly higher than in circulating CD4+ T cells (P = 0.034).
Fig. 2.  NKG2D expression on tumor infiltrating CD8+ T 
cells or NK cells.
 a: NKG2D expression on CD8+ T cells in tissue of 
colorectal cancer was significantly lower than that 
on circulating CD8+ T cells (P = 0.0079). 
b: NKG2D expression on NK cells in tissue of col-
orectal cancer was significantly lower than on cir-
culating NK cells (P < 0.0001). 
types of cancer patients, but this has not yet been 
determined in colorectal cancer.  Therefore, we 
first determined NKG2D expression on circulating 
CD8+ T lymphocytes and NK cells in both normal 
controls and colorectal cancer patients.  NKG2D 
expression of circulating CD8+ T lymphocytes in 
colorectal cancer patients (73.6 ± 19.6%) was sig-
nificantly lower than that in normal controls (84.5 
± 16.0%; P = 0.01; Figs. 1a and b).  Furthermore, 
NKG2D expression of circulating NK cells in col-
orectal cancer patients (86.3 ± 7.3%) was signifi-
cantly lower than those in normal controls (90.0 ± 
6.2%; P = 0.037; Figs. 1c and d). 
 
NKG2D expression on CD8+ T cells and NK 
cells in the tissue of colorectal cancer
 
We then determined NKG2D expression on CD8+ 
T cells and NK cells obtained from colorectal can-
cer tissue.  NKG2D expression on CD8+ T cells in 
the tissue of colorectal cancer (40.0 ± 14.9%) was 
significantly lower than that of circulating CD8+ T 
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Table 1.  The frequency of NKG2D+CD4+ T cells 
and clinicopathological characteristics in col-
orectal cancer patients
 Number NKG2D+CD4+  P
 of patients T cells (%) value
Depth of invasion*
 M/SM/MP   6 7.4 ± 6.9 0.22
 SS/SE/SI (A/AI)  25 3.9 ± 1.9
Lymph node metastasis 
 Absent 17 5.0 ± 4.4 0.71
 Present 14 4.1 ± 2.3
Lymphatic invasion†
 ly0/1 14 5.7 ± 4.9 0.24
 ly2/3 17 3.7 ± 1.7
Vascular invasion‡
 v0/1 14 5.6 ± 4.8 0.21
 v2/3 17 3.7 ± 2.0 
Liver metastasis
 Absent 28 4.6 ± 3.7 0.53
 Present  3 5.0 ± 2.6
Stage of disease
 Stage I/II 17 5.0 ± 4.4 0.71
 Stage III/IV 14 4.1 ± 2.3
* M, tumor invasion of mucosa; SM, tumor invasion of sub-
mucosa; MP, tumor invasion of muscularis propria; SS, 
tumor invasion of subserosa; SE, tumor invasion of sero-
sal; SI, direct tumor invasion of other organs or structures; 
A, tumor invasion through muscularis propria; AI, direct 
tumor invasion of other organs or structures.
† Lymphatic invasion: ly0–ly3, grade of lymphatic vessel 
invasion.
‡ Vascular invasion: v0–v3, grade of vascular invasion.
Fig. 4.  Cytokine profile of 
CD4+ T cells. 
   a:  IFN-gamma.
 b:  IL-10.
 c:  TGF-beta 1.
  MFI, mean fluorescence in-
tensity.  
cells (67.7 ± 22.0%; P = 0.0079; Fig. 2a).  NKG2D 
expression on NK cells in the tissue of colorectal 
cancers (34.8 ± 15.1%) was also significantly lower 
than that of circulating NK cells (86.6 ± 8.9%; P < 
0.0001; Fig. 2b).
 
  
Increased NKG2D+CD4+ T cells among 
TILs and in peripheral blood in colorectal 
patients 
 
CD4+ T cells in peripheral blood were significantly 
more positive for NKG2D in colorectal cancer pa-
tients (5.0 ± 4.6%) than that in normal controls (3.0 
± 2.2%; P = 0.048; Figs. 3a and b).  There were sig-
nificantly more NKG2D+CD4+ T cells in the tis-
sue of colorectal cancers (16.5 ± 16.6%) than those 
in peripheral blood (4.1 ± 1.7%; P = 0.034; Fig. 3c).
 Table 1 shows the correlation between the fre-
quency of NKG2D+CD4+ T cells and various clin-
icopathological factors.  No significant differences 
in the frequency of NKG2D+CD4+ T cells were 
observed in terms of depth of invasion, lymph node 
metastasis, liver metastasis and stage of disease.
 
 
 
Cytokine profile of NKG2D+CD4+ T cells in 
patients with colorectal cancer
 
Finally, we determined the cytokine profile of 
NKG2D+CD4+ T cells to show their immune 
suppressive function.  NKG2D+CD4+ T cells pro-
duced significantly less IFN-  than NKG2D-CD4+ 
T cells (Fig. 4a).  On the other hand, expression 
of the immune suppressive cytokines, IL-10 and 
TGF- 1, by NKG2D+CD4+ T cells was signifi-
cantly increased compared to NKG2D-CD4+ T 
cells (Figs. 4b and c).
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Discussion
 
CD8+ T cells and NK cells are thought to play an 
important role in the control of tumors as a result 
of their cytotoxic activity and by releasing soluble 
factors.  It has been reported that the functions of 
CD8+ T cells and NK cells are impaired in can-
cer patients, which is related to immune evasion 
by cancer.  Although the detailed mechanisms 
responsible for impaired function of CD8+ T cells 
and NK cells remain unclear, recent studies dem-
onstrated that decreased NKG2D expression on 
CD8+ T cells and NK cells was closely related 
to this phenomenon (Groh et al., 2002; Wu et al., 
2004).  In the present study, we demonstrated that 
the NKG2D expression of circulating CD8+ T cells 
and NK cells in colorectal cancer patients was 
significantly lower than that in normal controls. 
Furthermore, the reduction in NKG2D expression 
on CD8+ T cells and NK cells in the tissue of col-
orectal cancer was more striking than in peripheral 
blood.  We have previously shown that NKG2D 
expression significantly correlated with IFN-  pro-
duction in CD8+ T cells in patients with gastric 
cancer, indicating that downregulated NKG2D ex-
pression is closely related to the low responsiveness 
of CD8+ T cells to cancers (Osaki et al., 2007). 
Moreover, Groh et al. (2002) reported that NK-
G2D-low MART-1 specific CD8+ T cells isolated 
from TILs from a MIC-positive melanoma showed 
no or little induction of IFN-  after stimulation with 
MART-1 peptide, while a substantial proportion of 
identically treated NKG2D high MART-1-specific 
T cells from a MIC-negative melanoma produced a 
strong IFN-  response.  With regard to the function 
of NK cells, it has been demonstrated that down-
regulated NKG2D expression correlated with a 
reduction in cytotoxic activity by NK cells (Wu et 
al., 2004).  Therefore, the downregulated NKG2D 
expression of CD8+ T cells and NK cells observed 
in cancer tissue and peripheral blood in the pres-
ent study might be one of the key mechanisms by 
which colorectal cancer impairs the function of im-
mune cells such as CD8+ T cells and NK cells. 
 NKG2D can be induced on human CD4+ T 
cells by TCR-CD3 complex stimulation (Groh et 
al., 2003).  A previous study demonstrated that in-
creased populations of CD4+ T cells among TILs 
and in peripheral blood were positive for NKG2D 
in cancer patients with breast, lung, colon and 
ovarian carcinomas and melanomas (Groh et al., 
2006).  In the present study, we have also demon-
strated that the frequency of NKG2D+CD4+ T 
cells in patients with colorectal cancer is signifi-
cantly more than in normal controls.  Furthermore, 
the increased population of NKG2D+CD4+ T 
cells in the tissue of colorectal cancer was more 
striking than that in peripheral blood.  Those in-
creased NKG2D+CD4+ T cells produced less IFN-
 than NKG2D-CD4+ T cells.  On the other hand, 
NKG2D+CD4+ T cells produced more immuno-
suppressive cytokines, such as IL-10 and TGF- 1 
than NKG2D-CD4+ T cells, indicating that the 
increased number of NKG2D+CD4+ T cells we 
observed in colorectal cancer patients in the pres-
ent study had immunosuppressive properties and 
might correlate with immune evasion in colorectal 
cancer patients.  To the best of our knowledge, this 
study is the first to demonstrate decreased NKG2D 
expression on CD8+ and NK cells and an increased 
population of NKG2D+CD4+ T cell with immune 
suppressive function in colorectal cancer.
 The role of increased NKG2D+CD4+ T cells 
we observed in the present study in clinical settings 
remains unclear.  In fact, the increased frequency 
of NKG2D+CD4+ T cells in peripheral blood was 
not correlated with disease progression, indicat-
ing that an increase in NKG2D+CD4+ T cells in 
peripheral blood might be an early event in the 
progression of colorectal cancer.  On the other 
hand, some paper demonstrated that the presence 
of immune cells with immunosuppressive proper-
ties, such as Regulatory T cells which were char-
acterized by CD4+Foxp3+ T cells, in the tissue of 
carcinoma was associated with poor outcome in 
various solid tumors, including ovarian (Curiel et 
al., 2004; Sato et al., 2005), pancreatic (Hiraoka et 
al., 2006), and hepatocellular carcinoma (Kobayashi 
et al., 2007; Gao et al., 2007).  In fact, the increased 
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population of NKG2D+CD4+ T cells in the tissue 
of colorectal cancer was more striking than that in 
peripheral blood in the present study.  Although we 
were not able to determine the prognostic signifi-
cance of tumor-infiltrating NKG2D+CD4+ T cells 
due to small number of data, it is likely that tumor-
infiltrating NKG2D+CD4+ T cells is associated 
with poor prognosis in colorectal cancer.  Further 
investigation to show the prognostic significance of 
increased tumor-infiltrating NKG2D+CD4+ T cells 
is imperative. 
 The mechanisms by which NKG2D+CD4+ T 
cells increase remains unclear in the present study. 
In this regard, Groh et al. (2006) demonstrated that 
expansion of the NKG2D+CD4+ T cell population 
was dependent on the presence of tumor-associated 
MICA and correlates with serum concentrations 
of sMICA in cancer patients.  In the present study, 
however, there was no difference in the concentra-
tion of sMICA between normal controls and col-
orectal cancer patients (data not shown).  We are 
currently planning to perform some experiments 
to investigate the detailed mechanisms that induce 
expansion of NKG2D+CD4+ T cells in colorectal 
cancer patients.
 In conclusion, our data demonstrate decreased 
NKG2D expression on both CD8+ T cells and 
NK cells and an increase in the NKG2D+CD4+ 
T cell population in colorectal cancer patients. 
NKG2D+CD4+ T cells exhibit immune suppressive 
function by producing cytokines, such as IL-10 and 
TGF- 1.  Therefore, the MIC-NKG2D system might 
more exclusively contribute to immunosuppres-
sion by tumors in colorectal cancer.  On the other 
hand, the mechanisms by which NKG2D+CD4+ T 
cells increase are still unknown.  Further investiga-
tion to show the mechanisms leading to increased 
NKG2D+CD4+ T cells is urgently required.
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